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Edited by Robert BaroukiAbstract We developed a transgenic (Tg) rat model that overex-
presses human proadrenomedullinN-terminal 20 peptide (PAMP)
only and then compared the eﬀects of unilateral nephrectomy fol-
lowed by a high salt diet for ﬁve weeks in Tg andwild-type rats.We
found that systolic blood pressure was signiﬁcantly lower in Tg
UNX rats and cardiac hypertrophy and myocardial ﬁbrosis was
also attenuated in Tg rats. Evaluation of gene expression showed
suppression of cardiac local renin-angiotensin system (RAS) in Tg
rat. These results suggest that in addition to reducing blood pres-
sure, PAMP suppresses cardiac hypertrophy through negative
regulation of the local cardiac RAS.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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First identiﬁed as a novel vasodilator peptide [1], adreno-
medullin (AM) is now known to also exert a positive inotropic
eﬀect in the heart [2], act as an anti-apoptotic and anti-prolif-
erative factor in an endothelial cell line [3,4], inhibit angioten-
sin II-stimulated aldosterone secretion in adrenal gland [5,6],
and exert a diuretic and natriuretic eﬀect in kidney [7]. AM
is biosynthesized from a precursor, proadrenomedullin, the
N-terminal region of which also contains proadrenomedullin
N-terminal 20 peptide (PAMP), a 20-amino acid peptide that
is released at the same time as AM and, like AM, is ubiqui-
tously distributed in rat tissues. At present, much less is known
about the function(s) of PAMP than about those of AM. It is
known that, like AM, PAMP exerts a hypotensive eﬀect,
though a less potent one than AM [8], and that in rat
PAMP-evoked declines in blood pressure are accompanied
by inhibition of catecholamine release [9,10]. In addition,
PAMP inhibits aldosterone secretion from adrenal gland more
potently than does AM [11]. Aside from these few studies,
however, little is known about the activities of this ubiquitous
peptide. Therefore, to better understand some of the functions*Corresponding author. Fax: +81 985 85 6596.
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doi:10.1016/j.febslet.2005.08.007of PAMP, we developed a rat model that overexpresses human
(h)PAMP and examined its response when subjected to unilat-
eral nephrectomy followed by high salt loading (UNX hyper-
tension model) [12].2. Materials and methods
2.1. Plasmid construction
We constructed a PAMP transgene driven by the potent chicken b-
actin promoter as shown in Fig. 1. A segment of hPAMP cDNA
(GeneBank Accession No. NM 001124) in which the codon encoding
Lys73 (AAG) of preproadrenomedullin was changed to a stop codon
(TAG) was subcloned into pCAGGS vector [13]. The resultant plas-
mid, pCAGGS-hPAMP, which also contained the chicken b-actin pro-
moter, was conﬁrmed by DNA sequencing using standard techniques.
2.2. Generation of transgenic rats
After excising the transgene from pCAGGS-hPAMP by digestion
with Sal I and BamH I, the hPAMP DNA fragment was puriﬁed by
gel electrophoresis and dissolved in buﬀer for pronuclear microinjec-
tion into fertilized ova from superovulated Wistar rats. Once the rats
were born, genomic DNA was puriﬁed from the tips of their tails,
and potential transgenic (Tg) founders were screened by PCR using
primers and probe speciﬁc to hPAMP transgene.
This investigation conformed to the guidelines set forth in the Guide
for the Care and Use of Laboratory Animals published by the US Na-
tional Institutes of Health (NIH Publication No. 85-23, revised 1996).
2.3. Experimental protocol
PAMP Tg and wild-type rats were subjected to unilateral nephrec-
tomy and were then fed a high salt diet containing 8% NaCl for ﬁve
weeks. Blood pressures and heart rates were monitored throughout
the experimental period. At the end of ﬁve weeks, the rats were sacri-
ﬁced by decapitation and the hearts and samples of blood collected.
The hearts were cut in two, after which one portion was incubated with
4% paraformaldehyde for later histopathological evaluation, and the
remainder was kept in liquid nitrogen for later gene and protein eval-
uation.
2.4. Measurement of plasma and tissue hPAMP in Tg rats
Levels of hPAMP in plasma and various tissues from Tg rats were
measured using a radioimmunoassay method (RIA) as previously de-
scribed [1]. This assay was highly selective for hPAMP and showed
no cross-reactivity with rat PAMP.
2.5. Quantiﬁcation of gene expression using real-time PCR
Total RNA was isolated as described previously [14], after which
1-lg samples were reverse transcribed using SuperScript II reverse
transcriptase (Invitrogen), and the resultant cDNAs were subjected
to real-time quantitative PCR (Prism 7700 Sequence Detector, Appliedblished by Elsevier B.V. All rights reserved.
Fig. 1. Schematic diagram of the hPAMP transgene construct. The codon encoding Lys73 (AAG) in the preproadrenomedullin gene was changed by
a stop codon (TAG), after which the gene was inserted to the pCAGGS vector containing the chicken b-actin promoter.
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transgene expression were, 5 0-GCAACGTGCTGGTTATTGTG-30
(sense) and, 5 0-CCAGCCACCACCTTCTGATA-3 0 (antisense); the
probe used to detect hPAMP transgene was 5 0-TGCCCTCCCATA-
TGTCCTTCCGAGTGAGAG-3 0. The primers used to assess renin
mRNA expression were, 5 0-GCTACATGGAGAATGGGACTGAA-
3 0 (sense) and, 5 0-ACCACATCTTGGCTGAGGAAAC-3 0 (antisense);
the probe used to detect renin cDNA was 5 0-CCATCCACTATG-
GATCAGGGAAGGTCAA-3 0. The primers used to assess ACE
mRNA expression were 5 0-CTGCCTCCCAACGAGTTAGAA-30
(sense) and 5 0-CGGGACGTGGCCATTATATT-3 0 (antisense); the
probe used to detect ACE cDNA was 5 0-AAATGGCACTTGTCTGT-
CACTGGAGCC-3 0.
2.6. Histopathology
Heart specimens previously ﬁxed in 4% paraformaldehyde were
embedded in paraﬃn and cut into 4-lm-thick sections. The sections
were then deparaﬃnized in xylene, hydrated in a graded ethanol series
(100%, 90% and 70%) in distilled water and stained with either hema-
toxylin/eosin (HE) or Sirius red. Immunohistochemical staining was
performed with a polyclonal antibody to hPAMP. After HE staining,
the cross-sectional areas of the cardiac myocytes were measured and
compared as an index of cardiac hypertrophy. Myocardial ﬁbrosis
showed red after Sirius red staining, and was quantiﬁed as a function
of the intensity of the red signal determined using WinRoof image
analysis software (Mitani Corporation, Japan).
2.7. Calculations and statistics
Results are expressed as means ± S.E.M. Data are normally distrib-
uted and unpaired Student t tests were used to assess the signiﬁcance of
diﬀerences between two groups. Values of P < 0.05 were considered
signiﬁcant.3. Results
3.1. Success of the transgenic model
The potential transgenic rat was identiﬁed by detection of
the hPAMP transgene in rat tail tips using real-time quanti-
tative PCR. Homozygosity was veriﬁed by mating with
wild-type Wistar rats where all newborns were expected to
be heterozygous. Among seven positive founders which were
identiﬁed by tail tip genotyping, two founders were barren-
ness and one was suﬀered genomic transmission loss. The
other four founder lines were analyzed and one founder line
in which transgene was the highest expressed was multiplied.Because of the small number of newborns from homozygous
rat, heterozygous rats were used in all the experiments. Hu-
man PAMP protein level in Tg rat tissue was conﬁrmed by
immunohistochemistry method using an antibody speciﬁc to
hPAMP (Fig. 2). Moreover, high levels of hPAMP protein
were detected in the plasma and various tissues by RIA meth-
od (Table 1). Despite of the high level of plasma hPAMP
(21 ± 7.7 fmol/ml), there was no diﬀerence in the blood pres-
sures or heart rates of hPAMP Tg rats and their wild-type
littermates (data not shown).
3.2. Cardiovascular eﬀects of hPAMP overexpression in the
UNX hypertension model
To evaluate the function of PAMP in more detail, Tg and
wild-type rats were fed a diet containing 8% NaCl following
unilateral nephrectomy, which is a well-established protocol
for inducing hypertension [12]. As anticipated, blood pressures
in both wild-type and Tg UNX rats increased steadily during
their ﬁve weeks on the high salt diet; however, the increase
in pressure was signiﬁcantly attenuated in Tg rats (Fig. 3A),
which is consistent with our earlier ﬁndings indicating PAMP
to be a hypotensive peptide [8]. By contrast, heart rate was not
signiﬁcant diﬀerent in two groups (Fig. 3B).
Cardiac hypertrophy was also detected in the wild-type rats,
but was not seen in the Tg rats (Fig. 4A). After ﬁve weeks of
salt loading, the average heart weight-to-body weight ratio
(mg/g) was signiﬁcantly attenuated in Tg rats compared with
Wt ones (Table 2), and cardiac myocytes showed substantially
smaller cross-sectional areas in former than the latter. In addi-
tion, staining of heart tissue sections with Sirius red showing
the presence of pronounced myocardial ﬁbrosis in wild-type
rats, but not in Tg rats (Fig. 4B).
Finally, we investigated a potential mechanism of PAMPs
cardiovascular eﬀects by evaluating renin–angiotensin system
(RAS)-related gene expression in the heart tissues of the two
rat types. We found that the mRNA expression of angiotensin
I converting enzyme (ACE) was reduced in Tg rats to about
60% of that seen in samples from wild-type rats (Fig. 5A).
Correspondingly, cardiac renin gene transcription was about
2.5-fold higher in Tg than wild-type rats (Fig. 5B), which likely
reﬂects reduced cardiac angiotensin II production [15].
Table 1
Human PAMP levels in tissue and plasma of Tg and Wt rats
Plasma (fmol/ml) Heart (fmol/ml) Kidney (fmol/ml) Pancreas (fmol/ml) Lung (fmol/ml) Liver (fmol/ml)
Tg 21 ± 7.7 180 ± 43 255 ± 38 106 ± 35 79 ± 31 7.2 ± 0.6
Wt ND ND ND ND ND ND
ND, not detected.
Fig. 2. Representative immunohistochemical staining of hearts and kidneys from transgenic rats and wild-type littermates. Sections were stained
with polyclonal antibody to hPAMP. (A) Heart of Wt rat. (B) Heart of Tg rat. (C) Kidney of Wt rat. (D) Kidney of Tg rat.
Fig. 3. Time-dependent changes in systolic blood pressure (SBP) (A) and heart rate (HR) (B) in wild-type (Wt) and transgenic (Tg) rats during ﬁve
weeks of salt loading following unilateral nephrectomy. Data were collected using the tail cuﬀ method and are expressed as means ± S.E.M. n = 10 in
the wild-type group and n = 11 in the Tg group; \P < 0.05 vs. wild-type rats.
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It is unique that AM and PAMP are both biosynthesized
from the same gene. Therefore, caution should be taken when
using cDNA of preproadrenomedullin to generate transgenic
animals. If the whole cDNA is used as the transgene construct,
it is more likely to produce not only PAMP but also AM, lead-
ing to the diﬃculty of functional analysis. With this in mind,
we developed transgenic rats with human cDNA fragmentwhich was deleted AM coding region and contains genes cod-
ing PAMP only. By this means, PAMP-transgenic rat resulted
in increased PAMP expression without simultaneous increase
of AM.
Although PAMP is cleaved from the same precursor as AM,
its level in most tissues is no more than 0.1 fmol/mg, which is
much lower than AM levels [16]. This may be explained by its
rapid degradation by neutral endopeptidase, a protease that
also plays a key role in the degradation of human atrial
Fig. 4. (A) Representative HE-stained sections of heart tissue from wild-type (Wt) and transgenic (Tg) rats (upper panel; magniﬁcation, 400·) with
cross-sectional area (lower panel). (B) Representative sections of heart tissue fromWt and Tg rats stained with Sirius red (upper panel; magniﬁcation,
200·) and optical density of the red signals, which is indicative of the degree of myocardial ﬁbrosis (lower panel). Data are expressed as
means ± S.E.M. n = 10 in the wild-type group and n = 11 in the Tg group; \P < 0.05 vs. wild-type rats.
Table 2
Parameters of rats in Tg and Wt group after ﬁve weeks salt loading
Wt Tg
Body weight gain (g) 126 ± 41 119 ± 18
Heart weight/body weight
(mg/g)
3.5 ± 0.11 2.99 ± 0.1*
Urinary sodium excretion
(mmol/24 h)
18.51 ± 10.73 14.49 ± 6.1
Plasma creatinine (mg/dl) 0.46 ± 0.24 0.36 ± 0.1
Data are means ± S.E.M.
*P < 0.05 vs Wt rats.
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tissue PAMP levels are increased several hundred fold or more,
thus provides an especially useful means to study the biological
activity of PAMP.
Previous studies have shown that, like AM, PAMP is a
hypotensive peptide, though it is much less potent than AM
[8]. On the other hand, examination of renal sympathetic nerve
activity revealed that, distinct from AM, PAMP exerts a neg-
ative eﬀect of sympathetic excitation by inhibiting catechol-
amine release [9,10]. In the present study, we observed that
the rise in blood pressure normally seen in UNX animals
was stunted in hPAMP Tg rats, which is consistent with
PAMPs hypotensive eﬀects. In addition, both cardiac hyper-Fig. 5. Relative levels of mRNA expression of angiotensin I converting enzym
PCR. Levels of ACE and renin mRNA were normalized to that of GAPDHm
in each group; \P < 0.05 vs. wild-type rats.trophy and ﬁbrosis, which were quite pronounced in wild-type
UNX rats, were largely absent in the Tg animals. It is not clear
if this is a consequence of the lowered blood pressure or not,
for recent studies have shown that cardiac hypertrophy and
ﬁbrosis are independent of blood pressure, but are instead
closely related to the activity of a local cardiac RAS [18–21].
The circulating RAS has been studied for many years, and
the importance of its relationship to the development of car-
diovascular disease is well established [22]. However, recent
investigations have shown that a local cardiac RAS plays a
pivotal role in hypertensive cardiac hypertrophy, and that
anti-RAS drugs, such as ARB and ACE inhibitors, eﬀectively
counter its eﬀects [18,22]. Consistent with those ﬁndings, we
observed that cardiac ACE gene transcription was downregu-
lated in (h)PAMP Tg rats, which would be expected to reduce
local angiotensin II production, and that local renin gene tran-
scription was upregulated, which is consistent with an earlier
report that angiotensin II exerts powerful negative feedback
control over renin gene expression [15].
A limitation of the present study is that the role played by
local sympathetic nerve activity in the observed eﬀects of
PAMP was not investigated. Given the previously reported
inhibitory eﬀect of PAMP on renal sympathetic nerve activity
and catecholamine release [9,10], it is plausible that cardiac
sympathetic nerve activity was also suppressed in the (h)
PAMP Tg rats, which could in turn result in suppression ofe (ACE) and renin in heart tissues determined by real-time quantitative
RNA in the same samples. Data are expressed as means ± S.E.M. n = 6
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directly to suppress the cardiac RAS or indirectly via an eﬀect
on sympathetic nerve activity or via both pathways. In that
regard, although the signal transduction pathway activated
by AM has been well studied, not even PAMPs receptor has
yet been identiﬁed. Identiﬁcation of that receptor will be a
key step toward more fully understanding PAMPs activities
and their mechanisms. Because of the limitation of this classi-
cal transgenic approach in the present experiment, the results
might be prone to artifacts and the signiﬁcance of this study
is limited to some extent.
We have previously revealed that PAMP is a hypotensive
peptide and the understanding has been extended in this study
that PAMP may also attenuate cardiac hypertrophy and myo-
cardial ﬁbrosis which suggest the possible clinical implication
in the future.
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